Emergent Biosolutions Inc. (EBS) Stock Price & Analysis
Emergent Biosolutions Inc. (EBS) fell 0.63% to USD 7.95 as of June 10, 2026 at 08:05 UTC, according to Nexqual real-time market data.
EBS last closed at USD 8; the session ranged USD 7.56–8.16 on volume of 715,618 shares. Market capitalization is $410.19M, with a 52-week range of USD 5.62–14.06 (NYQ). Source: Nexqual, June 10, 2026 at 08:05 UTC.
Key Statistics (as of June 10, 2026 at 08:05 UTC)
| Price | USD 7.95 |
|---|---|
| Change | ▼ 0.63% (down) |
| Previous Close | USD 8 |
| Open | USD 8 |
| Day Range | USD 7.56 – 8.16 |
| 52-Week Range | USD 5.62 – 14.06 |
| Volume | 715,618 shares |
| Market Cap | $410.19M |
| Exchange | NYQ |
Technical Analysis (EBS)
Nexqual's technical model rates EBS "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 08:05 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.24 (neutral) |
| vs SMA50 | Below (USD 8.41) |
| MACD | -0.08 (negative) |
Analyst Ratings (EBS)
Wall Street analysts rate EBS "Strong Buy" based on 2 analysts, with a mean price target of USD 12 (range USD 12–12), per Nexqual as of June 10, 2026 at 08:05 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 12 |
| High Target | USD 12 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (EBS)
| Next Earnings Date | 2026-04-30 |
|---|---|
| EPS Estimate | USD 0.11 |
| Revenue Estimate | $177.50M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.21 vs est -0.25 ▲ beat |
| 2025-12-31 | USD -0.43 vs est 0.11 ▼ miss |
| 2025-09-30 | USD 1.06 vs est -0.12 ▲ beat |
| 2025-06-30 | USD 0.16 vs est -0.49 ▲ beat |
Source: Nexqual, June 10, 2026 at 08:05 UTC.
Financials & Fundamentals (EBS)
| Total Revenue | $676.80M |
|---|---|
| Revenue Growth (YoY) | -29.70% |
| Gross Margin | +47.49% |
| Operating Margin | +6.79% |
| Profit Margin | -1.27% |
| ROE | -1.60% |
| Debt / Equity | 111.76 |
| Current Ratio | 4.29 |
| Total Cash | $160.30M |
| Total Debt | $584.60M |
| Free Cash Flow | $256.21M |
Source: Nexqual, June 10, 2026 at 08:05 UTC.
Financial Health Score (EBS)
Nexqual rates Emergent Biosolutions Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 08:05 UTC.
| Growth | Critical — Revenue -29% YoY (annual), sharp decline |
|---|---|
| Profitability | Strong — Gross margin 47%, operating 7% |
| Balance Sheet | Mixed — $160M cash vs $585M debt |
| Cash Flow | Strong — FCF $256M, 34% margin |
| Efficiency | Critical — ROE -2%, ROA 3.4% |
Ownership (EBS)
| Insider Ownership | +3.86% |
|---|---|
| Institutional Ownership | +85.74% |
| Shares Outstanding | 51.60M |
| Float | 49.38M |
| Short % of Float | +19.22% |
Source: Nexqual, June 10, 2026 at 08:05 UTC.
Leadership (EBS)
Emergent Biosolutions Inc. is led by Joseph C. Papa Jr., M.B.A., R.Ph. (age 69), CEO, President & Director, per Nexqual as of June 10, 2026 at 08:05 UTC.
| CEO, President & Director | Joseph C. Papa Jr., M.B.A., R.Ph. (age 69) |
|---|---|
| Executive VP & CFO | Richard S. Lindahl (age 61) |
| Executive Vice President of Quality, Ethics & Compliance | Coleen Glessner (age 54) |
| Senior Vice President of Products Business | Paul A. Williams (age 58) |
| Senior Vice President of Manufacturing & Bioservices | William Hartzel (age 47) |
Major Backers & Investors (EBS)
Notable institutional backers of Emergent Biosolutions Inc. include American Century Companies Inc, Charles Schwab Investment Management, Inc., Acadian Asset Management. LLC, according to Nexqual as of June 10, 2026 at 08:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| American Century Companies Inc | 8.88% |
| Charles Schwab Investment Management, Inc. | 2.92% |
| Acadian Asset Management. LLC | 2.68% |
| Palisade Capital Management, L.P. | 2.33% |
| Charles Schwab | 1.92% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.4% |
| Vanguard Group | 11.72% |
| State Street | 9% |
| Dimensional Fund Advisors | 5.34% |
| Geode Capital | 2.47% |
Source: Nexqual, June 10, 2026 at 08:05 UTC.
From Emergent Biosolutions Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally.
- It operates through Commercial Products, MCM Products, and All Other Revenues segments.
- It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose.
- In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VIR | Vir Biotechnology, Inc. | USD 8.51 | ▼ 1.62% |
| QDEL | QuidelOrtho Corporation | USD 13.94 | ▼ 2.72% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 297.69 | ▼ 1.77% |
| BMRN | BioMarin Pharmaceutical Inc. | USD 57.91 | ▲ 2.01% |
| BHVN | Biohaven Ltd. | USD 11.09 | ▲ 2.69% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 08:05 UTC. This page is informational and not investment advice.